INVIEW Oncopanel All-in-one

Validated cancer panel for analysis of 597 key cancer-specific genes from tissue biopsy samples

INVIEW Oncopanel All-in-one is the most comprehensive gene panel available for optimized detection of tumor-specific genomic alterations. The oncology panel is optimized for formalin-fixed paraffin embedded (FFPE) or fresh-frozen tissue samples to deliver accurate genomic information on the status of clinically relevant driver mutations. This solid tumor panel uniformly and reproducibility covers the entire exons of about 600 characterized cancer genes, including tumor activators, tumor suppressors and biomarkers for drug resistance.

Typical applications for INVIEW Oncopanel All-in-one include:

• Comparative analysis of data from tissue biopsy and liquid biopsy
• Cancer screening by detection of well-known tumour-associated mutations such as driver mutations
• Determination of most important mutations for further studies

INVIEW Oncopanel All-in-one is suitable for clinical applications like:

• Molecular stratification
• Detection of resistance genes
• Guidance for treatment decisions
• Assignment of patients to clinical trials
• Post-treatment follow-up, especially for monitoring of multiple mutations

Highlights INVIEW Oncopanel All-in-one

• Highly uniform coverage of all exons in 597 cancer-associated genes
• Detection of relevant structural rearrangements and copy number variations (see “Product Details”)
• Ultra-sensitive detection levels down to 1% allele frequency
• Proprietary protocols for low-input DNA library preparation from challenging tissue and FFPE samples

Full service package offered by INVIEW Oncopanel All-in-one including

• Validated next-generation sequencing (NGS) cancer gene panel for analysis of key tumor-associated mutations in 597 protein-coding genes and select promoter regions
• Reproducible detection of single nucleotide polymorphisms (SNPs), insertions and deletions (InDels)
• Accurate detection of gene fusions between all covered genes, as well as 20 additional cancer-associated gene fusions
• Highly efficient target enrichment with latest Agilent SureSelect technology
• Reduced PCR-bias thanks to hybridization-based target capture approach
• Industry-leading sequence coverage and uniformity
• Detection of variants with sensitivity levels down to 1%
• Optimized protocols for low-input DNA library preparation from FFPE or fresh-frozen tissue samples
• Professional bioinformatical analysis with optional use of QIAGEN’s Ingenuity Variant Analysis software
• Analysis of copy number variations (CNVs) possible*

*CNV analysis should be performed in paired analysis of tumor versus matched normal tissue which is used as reference. In the case of tumor FFPE samples, we strongly recommend sending a healthy tissue FFPE sample from the same patient. Alternatively, tumor FFPE samples from at least seven other patients can be sent.

For fresh frozen tissue, we strongly advise that blood or healthy tissue from the same patient is sent. Alternatively, fresh frozen tissue from at least seven other patients or controls is recommended. 

Accepted starting material for INVIEW Oncopanel All-in-one

• DNA
• Blood
• FFPE tissue
• Fresh-frozen tissue

Specifications

Technology

• Hybridisation-based target capture using GATC optimised protocols and latest Agilent SureSelect technology
• Next-generation sequencing on Illumina platform

Deliverables

• FastQ files (sequences and quality scores)
• Alignment file (bam)
• SNP and InDel tables including annotated variants and effects (vcf, tsv)
• Tabels of copy gain and copy loss events (tsv)
• Table of gene fusion events (tsv)
• Comprehensive data analysis report (pdf)